LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Filippo de Marinis(Carlo Forlanini Hospital), Natasha B. Leighl(Princess Margaret Cancer Centre), Rossitza Krasteva Ruseva, Domenico Galetta(Istituto Tumori Bari), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Emilio Bria(Università Cattolica del Sacro Cuore), İlhan Hacıbekiroğlu(Sakarya University), Petr Opálka(Fakultní nemocnice Bulovka), Saadettin Kılıçkap(Memorial Ankara Hospital), Moana Hodari(AstraZeneca (United Kingdom)), Mehmet Alı Nahıt Şendur(Ankara Yıldırım Beyazıt University), Jaromı́r Roubec(Asklepios Fachkliniken München-Gauting), Susanne Lang(Ludwig-Maximilians-Universität München), Naomi Donner(AstraZeneca (United Kingdom)), Hakan Harputluoğlu(Inonu University), Silvia Novello(University of Turin), Christian Grohé(DRK Kliniken Berlin), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k